Logo

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab- biosimilar) at ESMO 2020

Share this

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab- biosimilar) at ESMO 2020

Shots:

  • The exploratory analyses of the P-III study evaluate the equivalent efficacy of Aybintio vs reference bevacizumab in combination with paclitaxel & carboplatin- q3w up to 6 cycles followed by Aybintio or reference bevacizumab as maintenance monothx. in 665 patients with metastatic/recurrent nsq. NSCLC
  • Results: previous analysis demonstrate ORR in PPS (50.1% vs 44.8%); expanded analysis showed the risk difference in best ORR by 11 & 17wks. (2.2% vs 2.4%); mean of maximum % change from baseline in tumor burden @24wks. (-27.8% vs -27.3%)
  • Aybintio is a biosimilar referencing Avastin and has received EC’s approval in Aug’2020 for mCRC- mBC- NSCLC- mRCC- epithelial ovarian- fallopian tube- primary peritoneal cancer and cervical cancer

­ Ref:  The Investor | Image: Samsung Bioepis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions